SCHEMBL10307883

SCHEMBL10307883

O=COc1cc(Cl)ccc1SSc1ccc(Cl)cc1C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.44
TP53 P04637 1/20 0.44
GAA P10253 3/20 0.43
TSHR P16473 2/20 0.43
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CASP1 P29466 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
POLB P06746 2/20 0.38
KDM4E B2RXH2 3/20 0.37
HSD17B10 Q99714 1/20 0.37
MYC P01106 2/20 0.36
NR4A1 P22736 1/20 0.36
HPGD P15428 2/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
PTGER1 P34995 1/20 0.35
GRIK1 P39086 2/20 0.35
GRIA2 P42262 2/20 0.35
F7 P08709 1/20 0.35
F3 P13726 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL823686 0.83 ALDH1A1 (0.61) ALDH1A1TP53GAATSHRCA1
SCHEMBL27893968 0.80 TSHR (0.58) ALDH1A1TP53GAATSHRCA1
SCHEMBL10307884 0.78 POLB (0.45) ALDH1A1SMN1; SMN2POLBKDM4EHSD17B10
SCHEMBL12052833 0.75 PTGER1 (0.49) ALDH1A1TP53GAATSHRCA1
SCHEMBL11704995 0.73 CYP3A4 (0.50) ALDH1A1TP53GAATSHRCA1
SCHEMBL10307880 0.73 POLB (0.65) ALDH1A1TSHRCA1CA2SMN1; SMN2
SCHEMBL4437995 0.72 ALDH1A1 (0.61) ALDH1A1TP53GAATSHRCA1
SCHEMBL12565537 0.71 AKR1C4 (0.41) ALDH1A1TP53GAATSHRCA1
SCHEMBL20053804 0.70 ALDH1A1 (0.57) ALDH1A1TP53GAATSHRCA1
SCHEMBL826739 0.69 SMN1; SMN2 (0.61) ALDH1A1TP53TSHRCA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8455688-B2 HDAC inhibitors LIXTE BIOTECHNOLOGY, INC. (US) 2013-06-04 US disclosed
US-20120178783-A1 HDAC INHIBITORS LIXTE BIOTECHNOLOGY, INC. 2012-07-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120178783-A1 HDAC INHIBITORS HDAC3, HDAC4, HDAC7 ALDH1A1 2826/4885TP53 795/4885GAA 4142/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.